C‐reactive protein and metabolic syndrome in women with previous gestational diabetes

This study evaluates the presence of metabolic syndrome (MS) and its association with C‐reactive protein (CRP) and other cardiovascular (CV) risk factors, in a sample of women with and without previous Gestational Diabetes (pGDM).

[1]  Stefano Del Prato,et al.  Early impairment of beta-cell function and insulin sensitivity characterizes normotolerant Caucasian women with previous gestational diabetes. , 2006, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[2]  Paul Zimmet,et al.  The metabolic syndrome—a new worldwide definition , 2005, The Lancet.

[3]  E. Yeh.  High‐sensitivity C‐reactive protein as a risk assessment tool for cardiovascular disease , 2005, Clinical cardiology.

[4]  Richard Kahn,et al.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. , 2005, Diabetes care.

[5]  A. de Leiva,et al.  Metabolic syndrome at follow-up in women with and without gestational diabetes mellitus in index pregnancy. , 2005, Metabolism: clinical and experimental.

[6]  Cristina Bianchi,et al.  Prevalence of the metabolic syndrome among Italian adults according to ATP III definition. , 2005, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[7]  G. Mitchell,et al.  Subclinical inflammation and vascular dysfunction in women with previous gestational diabetes mellitus. , 2005, The Journal of clinical endocrinology and metabolism.

[8]  T. Hansen,et al.  The prevalence of the metabolic syndrome in a danish population of women with previous gestational diabetes mellitus is three-fold higher than in the general population. , 2005, The Journal of clinical endocrinology and metabolism.

[9]  P. Kempler.  Learning from large cardiovascular clinical trials: classical cardiovascular risk factors. , 2005, Diabetes research and clinical practice.

[10]  H. Minuk,et al.  Metabolic syndrome. , 2005, Journal of insurance medicine.

[11]  G. Pagano,et al.  Prior gestational hyperglycemia: A long-term predictor of the metabolic syndrome , 2004, Journal of endocrinological investigation.

[12]  Paul M Ridker,et al.  Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? , 2004, Circulation.

[13]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[14]  Inflammation and glucose intolerance: a prospective study of gestational diabetes mellitus. , 2004, Diabetes care.

[15]  Bo Isomaa,et al.  A major health hazard: the metabolic syndrome. , 2003, Life sciences.

[16]  M. McCarthy,et al.  Insulin resistance and β‐cell dysfunction in normoglycaemic European women with a history of gestational diabetes , 2003, Clinical endocrinology.

[17]  R. D'Agostino,et al.  Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. , 2003, Diabetes.

[18]  J. Manson,et al.  C-Reactive Protein Is Independently Associated With Fasting Insulin in Nondiabetic Women , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[19]  M. Wolf,et al.  First-trimester C-reactive protein and subsequent gestational diabetes. , 2003, Diabetes care.

[20]  P. Ridker.  Clinical application of C-reactive protein for cardiovascular disease detection and prevention. , 2003, Circulation.

[21]  Catherine Kim,et al.  Gestational diabetes and the incidence of type 2 diabetes: a systematic review. , 2002, Diabetes care.

[22]  J. Ruidavets,et al.  Prevalence of insulin resistance syndrome in southwestern France and its relationship with inflammatory and hemostatic markers. , 2002, Diabetes care.

[23]  W. Dietz,et al.  Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. , 2002, JAMA.

[24]  T. Buchanan.  Pancreatic B-cell defects in gestational diabetes: implications for the pathogenesis and prevention of type 2 diabetes. , 2001, The Journal of clinical endocrinology and metabolism.

[25]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[26]  H. Brenner,et al.  Association between C-reactive protein and features of the metabolic syndrome: a population-based study. , 2000, Diabetes care.

[27]  P. Wahl,et al.  Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. , 2000, American journal of epidemiology.

[28]  N. Schneiderman,et al.  History of gestational diabetes, insulin resistance and coronary risk. , 1999, Journal of diabetes and its complications.

[29]  T. Buchanan,et al.  Gestational diabetes: risk or myth? , 1999, The Journal of clinical endocrinology and metabolism.

[30]  J. Lekakis,et al.  Impaired Endothelium-Dependent Vasodilatation in Women With Previous Gestational Diabetes , 1998, Diabetes Care.

[31]  R. DeFronzo.  Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. , 1997, The Netherlands journal of medicine.

[32]  B. Vohr,et al.  Lipid Levels in Former Gestational Diabetic Mothers , 1996, Diabetes Care.

[33]  B. Metzger.  Summary and Recommendations of the Third International Workshop-Conference on Gestational Diabetes Mellitus , 1991, Diabetes.

[34]  R. DeFronzo,et al.  Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease , 1991, Diabetes Care.

[35]  D. Coustan,et al.  Criteria for screening tests for gestational diabetes. , 1982, American journal of obstetrics and gynecology.